Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Claudication, Intermittent
Conditions
Claudication, Intermittent, Peripheral Artery Disease, Peripheral Vascular Diseases
Trial Timeline
Jun 15, 2021 → Dec 1, 2027
NCT ID
NCT04800692About Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine
Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine is a phase 1 stage product being developed by BioMarin Pharmaceutical for Claudication, Intermittent. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04800692. Target conditions include Claudication, Intermittent, Peripheral Artery Disease, Peripheral Vascular Diseases.
Hype Score Breakdown
Clinical
6
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04800692 | Phase 1 | Recruiting |
Competing Products
6 competing products in Claudication, Intermittent
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LLG783 + Placebo | Novartis | Phase 2 | 35 |
| ataciguat (HMR1766) + placebo + cilostazol | Sanofi | Phase 2 | 35 |
| Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 | Sanofi | Phase 2 | 35 |
| SL650472, Clopidogrel | Sanofi | Phase 2 | 35 |
| Sapropterin Dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 32 |
| Placebo + 375 mg CK-2017357 + 500 mg CK-2017357 | Cytokinetics | Phase 2 | 32 |